1. Bertsias G, Ioannidis JP, Boletis J et al. Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67 (2): 195–205.
2. Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69 (7): 1269–74.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40 (9): 1725.
5. Ревматология. Национальное руководство. Под ред. Е.Л.Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008: 720.
6. Насонова В.А. Системная красная волчанка. М.: Медицина, 1972: 246.
7. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35 (6): 630–40.
8. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904–14.
9. Petri M, Kasitanon N, Lee SS et al. Systemic Lupus International Collaborating Clinics. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum 2008; 58 (6): 1784–8.
10. Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69 (12): 2074–82.
11. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004: 440.
12. Jakods Y, Hoes J, Bijlsma J. EULAR recommendations on the management of systemic qlucocorticoid therapy in Rheumatic diseases. Ann Rheum Dis 2007; 66 (11): 8–9.
13. Panjwani S. Early Diagnosis and Treatment of Discoid Lupus Erythematosus. J Am Board Fam Med 2009; 22 (2): 206–13.
14. Muilins JF, Watts FL. Plaquenil in the treatment of lupus erythematosus. JAMA 1956; 161: 879–81.
15. Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33–51.
16. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358 (9): 929–39.
17. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80–5.
18. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988; 85: 23–9.
19. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med 2010; 9 (44): 20–3.
20. Кошелева Н.М., Хузмиева С.И., Алекберова З.С. Системная красная волчанка и беременность. II. Влияние системной красной волчанки на исходы беременности. Научно-практическая ревматология. 2006; 2: 52–9.
21. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199 (2): 127.e1–6.
22. Инструкция по медицинскому применению препарата Плаквенил®. http://www.rlsnet.ru/prep_index_id_33527.htm
Авторы
Н.А.Шостак, А.А.Клименко
Кафедра факультетской терапии им. А.И.Нестерова ГБОУ ВПО РНИМУ им. Н.И.Пирогова, Москва